Overview

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

Status:
Completed

Trial end date:
2005-06-01

Target enrollment:

Participant gender:

Summary

To demonstrate the efficacy and safety of aliskiren given to patients with essential hypertension, at doses of 75 mg, 150 mg and 300 mg alone, and in combination with hydrochlorothiazide (HCTZ)

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide